SCHEMBL68187

SCHEMBL68187

CCC[C@@H](C(N)=O)N(C)[C@H]1CC[C@@H]2CN(S(=O)(=O)c3ccc(OC)cc3)C[C@@H]21

nearest known ligand 0.45

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.45
CYP3A4 P08684 1/20 0.45
CYP2D6 P10635 1/20 0.45
CYP2C9 P11712 1/20 0.45
CYP2C19 P33261 1/20 0.45
CHRM5 P08912 2/20 0.42
GAA P10253 1/20 0.42
PKM P14618 3/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
CACNA1B Q00975 1/20 0.41
LMNA P02545 1/20 0.40
MAPT P10636 1/20 0.40
KMT2A Q03164 1/20 0.40
TSHR P16473 1/20 0.39
NPC1 O15118 1/20 0.39
PKLR P30613 1/20 0.39
RAB9A P51151 1/20 0.39
HPGD P15428 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL66893 0.89 MAPT (0.44) ALDH1A1L3MBTL1LMNAMAPTKMT2A
SCHEMBL65654 0.89 CACNA1B (0.44) ALDH1A1CYP3A4CYP2C19L3MBTL1CACNA1B
SCHEMBL66907 0.87 CACNA1B (0.47) CACNA1BKMT2A
SCHEMBL66028 0.87 CACNA1B (0.43) ALDH1A1GAACACNA1BKMT2ATSHR
SCHEMBL68722 0.86 CACNA1B (0.40) CACNA1B
SCHEMBL67478 0.84 HPGD (0.40) L3MBTL1CACNA1BLMNAKMT2AHPGD
SCHEMBL66035 0.83 CACNA1B (0.45) ALDH1A1CYP3A4CYP2C19L3MBTL1CACNA1B
SCHEMBL66689 0.82 MEN1 (0.43) L3MBTL1CACNA1BLMNAKMT2AHPGD
SCHEMBL67585 0.81 CACNA1B (0.42) ALDH1A1GAACACNA1BLMNAKMT2A
SCHEMBL67404 0.80 CACNA1B (0.47) GAAL3MBTL1CACNA1BHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8129417-B2 Substituted octahydrocyclopenta[C]pyrrol-4-amines as calcium channel blockers ABBOTT LABORATORIES (US) 2012-03-06 US claimed
US-20110281870-A1 NOVEL SUBSTITUTED OCTAHYDROCYCLOPENTA[C]PYRROL-4-AMINES AS CALCIUM CHANNEL BLOCKERS ABBOTT LABORATORIES (US) 2011-11-17 US claimed
US-20100130558-A1 NOVEL SUBSTITUTED OCTAHYDROCYCLOPENTA[C]PYRROL-4-AMINES AS CALCIUM CHANNEL BLOCKERS ABBOTT LABORATORIES (US) 2010-05-27 US claimed
US-8129417-B2 Substituted octahydrocyclopenta[C]pyrrol-4-amines as calcium channel blockers ABBOTT LABORATORIES (US) 2012-03-06 US disclosed
US-20110281870-A1 NOVEL SUBSTITUTED OCTAHYDROCYCLOPENTA[C]PYRROL-4-AMINES AS CALCIUM CHANNEL BLOCKERS ABBOTT LABORATORIES (US) 2011-11-17 US disclosed
US-20100130558-A1 NOVEL SUBSTITUTED OCTAHYDROCYCLOPENTA[C]PYRROL-4-AMINES AS CALCIUM CHANNEL BLOCKERS ABBOTT LABORATORIES (US) 2010-05-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100130558-A1 NOVEL SUBSTITUTED OCTAHYDROCYCLOPENTA[C]PYRROL-4-AMINES AS CALCIUM CHANNEL BLOCKERS CACNA1C, ORAI1, CACNA1S ALDH1A1 556/4885CYP3A4 1006/4885CYP2D6 617/4885
US-20110281870-A1 NOVEL SUBSTITUTED OCTAHYDROCYCLOPENTA[C]PYRROL-4-AMINES AS CALCIUM CHANNEL BLOCKERS CACNA1C, ORAI1, CACNA1S ALDH1A1 556/4885CYP3A4 1006/4885CYP2D6 617/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.